DAIC

JULY 31, 2024

It incorporates age, body mass index (BMI), and atrial fibrillation to aid in the diagnosis of HFpEF. The newly developed HFpEF-ABA score model estimates the probability of HFpEF in individual patients based on three simple clinical variables: age, BMI, and atrial fibrillation.

Heart Failure 111

Heart Failure Preserved Ejection Fraction Research Hospital 111

Circulation

JANUARY 22, 2025

Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrial fibrillation. Current consensus age- and BMI-stratified rule-in thresholds demonstrated only 65% specificity (95% CI, 57%72%).

Preserved Ejection Fraction 55

Preserved Ejection Fraction Outpatient Heart Failure BMI 55

Journal of Cardiovascular Electrophysiology

DECEMBER 17, 2024

Obesity is associated with reduced catheter ablation-induced scar formation on late-gadolinium enhancement MRI. Abstract Introduction Obesity is implicated in adverse atrial remodeling and worse outcomes in patients with atrial fibrillation. Ablation parameters and lesion delivery were not dependent on BMI.

Ablation 40

Ablation BMI Obesity Atrial Fibrillation 40

Circulation

NOVEMBER 11, 2024

The mean BMI was 27.9 kg/m2, with 4 classified as obese. Only one patient had paroxysmal atrial fibrillation, with a CHA2DS2-VASc score of 0. Echocardiography revealed structurally normal hearts with a mean left ventricular ejection fraction of 61% and a mean left atrial volume index of 24.8

Aneurysm 40

Aneurysm Stroke Strokes Atrial Fibrillation 40

Open Heart

AUGUST 5, 2022

Objective While greater body mass index (BMI) is associated with increased risk of developing atrial fibrillation (AF), the impact of BMI on outcomes in newly diagnosed AF is unclear. The study population comprised 40 482 participants: 703 underweight (BMI <18.5 kg/m 2 ), 13 095 normal (BMI=18.5–24.9

Atrial Fibrillation 52

Atrial Fibrillation BMI Outcomes Obesity 52

DAIC

JUNE 26, 2024

Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. The study analyzed the effects of semaglutide 2.4

Preserved Ejection Fraction 105

Preserved Ejection Fraction Obesity BMI Heart Failure 105